Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections.
Julia HerrmannAnne-Valérie BurgenerDaniel GoldenbergerJan RothMaja Weisser-RohacekPranita D TammaSarah Tschudin-SutterPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2023)
After excluding isolates with phenotypic ESBL-co-production, cefepime was not associated with adverse outcomes compared to carbapenems when used to treat BSIs caused by AmpC-PE. Our study provides evidence to support the use of cefepime as a safe treatment strategy for AmpC-PE BSI, particularly in clinically stable patients without initial renal impairment or increased susceptibility to neurological adverse events.